We previously showed that the specific PPARα agonist fenofibrate, an FDA-approved drug used to treat dyslipidemia with minimal activity toward PPARγ (Kim et al., 2016; Rosenson, 2008), upregulated PPARα target genes in the DRG and rescued the impaired axon growth in mice lacking fatty acid synthase in SGC (Avraham et al., 2020). Here, FASN is linked to metabolic syndrome.